anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a class of chalcone oxime derivatives having inhibiting effect on cancer cell tubulin polymerization, and a preparation method thereof. The class of chalcone oxime derivatives has the general formula shown in the specification. Experiments demonstrate that the novel chalcone oxime derivatives provided by the invention have obvious inhibiting effect on polymerization of cancer cell tubulin. Thus, the chalcone oxime derivatives provided by the invention can be used for preparing anti-cancer drugs. The invention also discloses a preparation method of the chalcone oxime derivatives. In the formula, R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are respectively selected from H, C1-5 alkyl, C1-5 alkoxy, halogen, halogen substituted C1-5 alkyl, nitro and amino.
The INCa recommendations of December 2016 propose the destruction or abstention-monitoring of high-grade histological cervical lesions (HSIL) as an alternative to conization under certain conditions. These are women under 30 years old, with a small lesion in colposcopy, without any sign of invasion, with a squamocolumnar junction seen. These women must accept the principle of regular monitoring by cytology and colposcopy +/- biopsy every 6 months for a maximum of 2 years. HSIL group 2 histological entities CIN2 and CIN3. It is recognized that CIN2 are associated with CIN1 and CIN3 biology whose diagnosis is the result of the subjectivity of colposcopy allowing cervical biopsy and the variability of pathological interpretation due to poor reproducibility of histological diagnosis. CIN2 regress spontaneously in more than 50% of cases at 1 year, either completely (no lesion) or partially (LSIL low grade lesions). No invasive lesions are diagnosed over 2-year observation periods. Among the clinical, pathological and virological criteria, only the initial HPV genotyping seems to have a prognostic influence. There is therefore no strong scientific argument for routine conization in a woman over 30 years of age with a CIN2 lesion extended over more than two quadrants. In addition, conization is associated with an obstetrical risk (prematurity) and post-therapeutic colposcopic cervical stenosis complicates subsequent monitoring in case of abnormal smears. These considerations encourage the extension of the indications of abstention monitoring in the management of women with CIN2 wishing to procreate with an extension of the age to 39 year old, with no limit of size of the lesion and to satisfactory colposcopy
A device for gathering vital sign and other heath indicator data. The device is constructed to register with a person’s anatomical structure in a predictable fashion, and to include integrated sensors positioned to register with specific anatomical portions of the person. Accordingly, relevant data and assessment may be performed passively, e.g., during physical contact/engagement of the patient with the sensors of the device, which may be for, example, a chair or other piece of furniture in which the patient may sit. The device may analyze gathered sensor data and draw clinical assessment conclusions. Data analysis may be done at the device, or remotely. Vital sign/data and/or assessment conclusions may be displayed to the caregiver only, e.g., via a display device or via an EHR or other computing system receiving data from the device. A separate display screen may display information to the patient for entertainment or instructive purposes.
This is a single-center study design, and 30 patients will be enrolled. Eligible patients will receive docetaxel at different dose levels according to the trial schedule. All the enrolled patients were treated with docetaxel during the first HIPEC treatment and cisplatin during the second HIPEC treatment at 43℃ for 1 hour. Four dosages of docetaxel were set up in the study. We decided to take the initial dose of 60mg/m2 and increase the remaining dose gradient by 5 mg/m2. The dosage of cisplatin was 75mg/m2. Time-to-event Bayesian Optimal Interval Design(TITE-BOIN) was used, with 3 patients as an observation group (i.e. a cohort), starting from a dose of 60mg/m2. The dose of docetaxel for patients in the next group was determined according to the incidence of dose-limiting toxicity (DLT) of the previous docetaxel dose level. Finally, the maximum tolerated dose (MTD) of docetaxel for HIPEC was calculated according to the incidence of dose-limiting toxicity.
SBRT is given during combined therapy to one of the lesions, 25Gy in 5 fractions over one week, conformally to maximally spare normal tissue or organ. Thymalfasin treatment is given twice a week with an interval of 3-4 days until tumor progression of other metastatic lesions. Tumor response is evaluated by assessing clinical and CT/MRI response for all the other measurable metastatic sites.
A retrospective analysis was conducted on 214 patients with PSVT recieving PFA who met the inclusion and exclusion criteria and visited at the First Affiliated Hospital of Ningbo University, the Third People's Hospital of Chengdu, the Xiamen Cardiovascular Hospital of Xiamen University, the First Hospital of Jilin University, the Seventh People's Hospital of Zhengzhou, Shanghai General Hospital, and Jiangxi Provincial People's Hospital from October 2022 to June 2024. These patients were included in the PFA group. Basic clinical information, procedural data, and the efficiency and safety post 1-year follow-up were collected and analyzed.
BACKGROUND: Diagnosis of left circumflex artery (LCx) myocardial infarctions via 12‑lead electrocardiogram (ECG) has posed a challenge to healthcare professionals for many years.
METHODS AND RESULTS: A retrospective observational study was performed to analyze patients admitted with myocardial infarction. The study used electronic medical records and specific ICD-10 codes to identify eligible patients, resulting in 2032 encounters. After independent adjudication of cardiac biomarkers, coronary angiography, and electrocardiographic changes, a final patient population of 58 encounters with acute occlusion myocardial infarction (OMI) with a culprit LCx lesion was established. OMI was defined as a lesion with either thrombolysis in myocardial infarction flow (TIMI) 0-2 or TIMI 3 with Troponin I > 1 ng/mL (Reference range 0.00-0.03 ng/mL). ECGs of these patients were then independently evaluated and grouped into 8 different classifications based on the presence or absence of ST elevation and/or depression in corresponding leads. ECG patterns and anatomical characteristics (proximal or distal to the first obtuse marginal artery) of the LCx lesions were then correlated. The appropriateness of triage and delay in reperfusion therapy were also assessed. Those with a left dominant or codominant circulation, and with LCx lesions proximal to the first obtuse marginal artery, were more likely to present with no or subtle ST-segment changes that led to delays in reperfusion therapy.
CONCLUSIONS: Patients with left or codominant coronary artery circulation, with OMI proximal to the first obtuse marginal artery, may be less likely to have "classic" findings of ST-segment elevation on ECG due to cancellation forces in the limb leads.
The invention relates to a cross-regional electronic medical record quick positioning and sharing system and a cross-regional electronic medical record quick positioning and sharing method. The system comprises a message source positioning device, a message transfer device, a message source cooperation device and a message queue manager. A distributed basic sanitary information application platform is integrally assembled based on transmission of messages, and cross-regional quick positioning and information sharing of electronic medical records and health records are realized in form of loose coupling. Based on existing distributed construction, an isomerous basic medical mechanism system is quickly accessed, and the places of the electronic medical records and health records are quickly positioned through a resource positioning device, and information is acquired, so that a lot of construction and operational and maintenance expenses can be saved. Integral personal lifelong medical data information is convenient to establish to ensure the continuity and the integrity of the electronic medical records and health records. Conditions of patients can be comprehensively mastered to truly realize synchronous prevention and treatment so as to avoid various repeated examinations, and thereby, a lot of treatment expenses are saved, and the doctor-patient relationship is improved.
The purpose of this research study is to observe the effects of using an FDA-approved rectal spacer device known as the SpaceOAR Hydrogel, which is a soft gel material used to create a space between the rectum and prostate during radiation treatment. The rectal spacer gel is made up of 90% water and 10% polyethylene glycol and is injected as a liquid through a needle inserted between the rectum and prostate. It will stay in place for about 3 months and is naturally absorbed into the body and removed through urine in about 6 months. By pushing the prostate further from the rectum with the hydrogel, it will help spare the rectum from receiving radiation during the standard of care stereotactic body radiation treatment participant will be receiving, along with the brachytherapy treatment. The hydrogel rectal spacer has been shown to be very safe and effective at reducing radiation dose to the rectum during external radiation treatments, but has not been well-studied when using a combination of Stereotactic Body Radiation Therapy (SBRT) and brachytherapy. The goal of this research is to determine how effective the SpaceOAR hydrogel rectal spacer is at decreasing radiation side effects that can occur in the rectum, which can include discomfort or bleeding. The researchers also want to see how the use of this device affects the doctor's ability to perform the brachytherapy implant safely and effectively.
Patients with Expiratory flow limitation will undergo a positive end-expiratory pressure trial to assess the level of positive end-expiratory pressure that eliminates the Expiratory Flow limitation. Positive end-expiratory pressure will be set at a fixed level of 4 cmH2O.
PCT No. PCT/HU95/00011 Sec. 371 Date Apr. 16, 1996 Sec. 102(e) Date Apr. 16, 1996 PCT Filed Apr. 25, 1995 PCT Pub. No. WO95/29172 PCT Pub. Date Nov. 2, 1995New inclusion complexes which are stable in their so-lid state formed of SIN-1A and cyclodextrins or cyclodextrin derivatives and optionally also containing ions as catalyst or stabilizer. The complexes release nitric oxide at room temperature upon dissolving in water or aqueous systems. The ions are preferably carboxylic acid anions such as acetate, formiate, propionate, ascorbinate, tartarate and/or lactate and/or inorganic acid anions such as phosphate, phosphite, borate, carbonate, hydrocarbonate, sulfate, sulfite and/or cations such as alkali and/or ammonium. Pharmaceutical compositions as well as kits containing the complexes. The kits are to be used as NO-liberating standards to release NO in a predictable amount and rate on dissolving in aqueous media. Processes for the preparation of the complexes by subjecting at a suitable pH SIN-1 to the catalytic action of ions to shift the equilibrium towards formation of SIN-1A in the presence of cyclodextrins or cyclodextrin derivatives capable to form inclusion complexes, whereby the SIN-1A formed is immediately complexed and stabilized and isolating in the solid state the obtained new complexes optionally containing ions. A preferred process includes reacting SIN-1 and a cyclodextrin or cyclodextrin derivative in the solid state in the presence of a salt as a catalyst by thoroughly admixing or milling the components together or by freeze drying an aqueous, oxygen-free solution containing the components, followed preferably by "second drying" in vacuo.
Several studies have reported an increased risk of chronic kidney disease (CKD) outcomes after long-term exposure (more than 1 year) to particulate matter with an aerodynamic diameter of ≤ 2.5 µm (PM2.5). However, the conclusions remain inconsistent. Therefore, we conducted this meta-analysis to examine the association between long-term PM2.5 exposure and CKD outcomes. A literature search was conducted in PubMed, Scopus, Cochrane Central Register of Controlled trials, and Embase for relevant studies published until August 10, 2023. The main outcomes were incidence and prevalence of CKD as well as incidence of end-stage kidney disease (ESKD). The random-effect model meta-analyses were used to estimate the risk of each outcome among studies. Twenty two studies were identified, including 14 cohort studies, and 8 cross-sectional studies, with a total of 7,967,388 participants. This meta-analysis revealed that each 10 μg/m3 increment in PM2.5 was significantly associated with increased risks of both incidence and prevalence of CKD [adjusted odds ratio (OR) 1.31 (95% confidence interval (CI) 1.24 to 1.40), adjusted OR 1.31 (95% CI 1.03 to 1.67), respectively]. In addition, the relationship with ESKD incidence is suggestive of increased risk but not conclusive (adjusted OR 1.16; 95% CI 1.00 to 1.36). The incidence and prevalence of CKD outcomes had a consistent association across all subgroups and adjustment variables. Our study observed an association between long-term PM2.5 exposure and the risks of CKD. However, more dedicated studies are required to show causation that warrants urgent action on PM2.5 to mitigate the global burden of CKD.
The present invention discloses a dry red persimmon wine and a brewing method thereof. The dry red persimmon wine is prepared from the effective active components of the following weight ratio effective range (measured by the total amount of 100 parts): 70 to 80 parts of persimmon fruit, 7 to 8 parts of camptotheca acuminata, 2 to 3 parts of blister beetle, 2 to 3 parts of catharanthus roseus, 2 to 3 parts of purpleflower crotalaria herb, 1 to 2 parts of mongolian snakegourd root, 1 to 2 parts of fig, 1 to 2 parts of hedyotic diffusa, 1 to 2 parts of Chinese lobelia, 1 to 3 parts of Herba Scutellariae Barbatae, 1 to 2 parts of scorpion and 1 to 2 parts of centipede. The dry red persimmon wine is prepared by processing the effective active components through leaching through multiple temperature change, fermentation leaching, dissolution, secondary fermentation and ageing storage under the action of mildew. Nutrition and antineoplastic active components leached from the effective active components are dissolved in a home-brewed fruit wine. The fruit wine is used as a carrier, which is extremely easy to accept by humans and is extremely easy to absorb by human bodies. The nutrition, the antineoplastic active components and the fruit wine can mutually benefit and enhance curative effects, and the dry red persimmon wine has the remarkable effect on the prevention and the cure of cancer diseases. The dry red persimmon wine of the present invention has the advantages of scientific prescription, unique extraction method, less investment and obvious effect, and the dry red persimmon wine is a valuable product capable of being developed.
Prevalence of chronic pain has been shown to be high after thermal injury. Post-burn neuropathic pain causes chronic disabilities that is often difficult to treat effectively.

To study changes in the pain network associated with neuropathic pain, magnetic resonance imaging(MRI) will be used to evaluate cerebral blood volume(CBV) in patients who was injuried by burn. Over the fifty participants will be recruited. The participants will be comprised 30 subjects with neuropathic pain caused by thermal injury and 20 healthy contols. The 30 patients with neuropathic pain will be comprised divided into 15 electrical injury group and 15 non-electrical burn injury group. The patients are included the patients with severe neuropathic pain that is rated at least 5 on the visual analogue scale (VAS), despite treatments with gabapentin medication and other physical modalities. The intensity of neuropathic pain will be measured using the visual analogue scale(VAS). Depressive mood will be assessed using the Beck Depression Scale. CBV maps will be compared between burn patients and controls. And the relationship between individual participant CBV(measured in voxels), BDS and VAS score will be also examined.
Pelvic organ prolapse (POP) markedly affects the quality of life of women, including significant financial burden. Using single-cell RNA sequencing, we constructed a transcriptional profile of 30,452 single cells of the uterosacral ligament in POP and control samples, which has never been constructed before. We identified 10 major cell types, including smooth muscle cells, endothelial cells, fibroblasts, neutrophils, macrophages, monocytes, mast cells, T cells, B cells, and dendritic cells. We performed subpopulation analysis and pseudo-time analysis of POP primary cells, and explored differentially expressed genes. We verified previous cell clusters of human neutrophils of uterosacral ligaments. We found a significant reduction in receptor-ligand pairs related to ECM and cell adhesion between fibroblasts and endothelial cells in POP. The transcription factors related to the extracellular matrix, development, and immunity were identified in USL. Here we provide insight into the molecular mechanisms of POP and valuable information for future research directions.
Neuromuscular blocking agents (NMBAs) are routinely used as standard part of a modern, balanced anesthesia regime. A residual duration of action exceeding the end of surgery, also called residual neuromuscular paralysis, is a common undesired side effect and increases the risk for postoperative pulmonary complications such as aspiration or pneumonia delaying patients' discharge from the post-anesthesia care unit. To limit the incidence of residual paralysis in daily anesthesia care, quantitative neuromuscular monitoring is recommended after injection of NMBAs. If a residual effect of a NMBA is detected at the end of surgery, reversal agents such as cholinesterase inhibitors, e.g. neostigmine or a selective relaxant binding agent, e.g. sugammadex can be administered. However, if reversal agents are not adequately dosed, the risk for a residual neuromuscular blockade re-occurs. Accordingly, neuromuscular monitoring is also useful to control the action of the administered reversal agents.

Although several techniques of neuromuscular monitoring are established in clinical practice, electromyography (EMG) and acceleromyography (AMG) are the most common quantitative neuromuscular monitoring devices. Electromyography, the gold standard for detecting residual neuromuscular block, is based on measuring summarized spikes of evoked muscle contractions. Acceleromyography measuring the acceleration of evoked muscle contraction is also commercially available and easy to use. This acceleration, however, can be measured both one-dimensionally and three-dimensionally.

This study evaluates the three described neuromuscular monitoring devices with regard to their precision to detect residual paralysis after administration of NMBAs and recurrence of neuromuscular blockade after administration of reversal agents in a clinical setting. We plan to include and randomize a total of 200 patients. The study participants will be recruited from patients scheduled for surgery at the Klinikum rechts der Isar der Technischen Universität München, Munich, Germany. In each patient, acceleromyography (either one- or three-dimensional) will be compared with the calibrated electromyography. The findings will help to indicate which neuromuscular monitoring device is most suitable for detecting residual paralysis and recurrent neuromuscular blockade.
The invention relates to a method for producing an anti-cancer agent based on a two-valent platinum co-ordination compound consisting in treating a humic substance-containing aqueous solution by said platinum compound. The co-ordination platinum compounds are embodied in the form of compounds selected from a potassium tetra- chloroplatinate, cis-dichloro-diamine platinate, hydrogen tetra-chloroplatinate and potassium tetra-bromoplatinate group. The treatment is carried out by means of a wave radiation action until the content of a high-molecular fraction in the humic substances is equal to or less than 5 %. Said wave radiation can be embodied in the form of a radiation selected from an ultrasound range of 18-66 kHz and a power of 0.5-5 W/cm3. The treatment is carried out for 5-20 minutes with a radiation power of 5 W/cm3 and a frequency of 22 kHz. Said wave radiation can be embodied in the form of a radiation selected from an microwave range of 30-0.3 GHz and a power of 0.5-50 kW. The temperature of a processable product is maintained within a range of 60-70 °C for 30-90 minutes at the power of the microwave radiation of 5/W/cm3 and a frequency of 2.45 GHz.
On the day after your admission, you will start receiving radiation therapy (TBI). Radiation will be given to you 2 times a day for 3 days. On the next day, you will then begin your chemotherapy with a drug called etoposide. This medicine will be given to you by an infusion into your bloodstream through a small tube in the vein of your arm for one day. After the etoposide treatment, on the next day you will receive cyclophosphamide (also known as Cytoxan) for 2 days. When you are given cyclophosphamide, you will also be given a medication called MESNA to help protect your bladder from damage. After you have completed the cyclophosphamide you will rest one day without any anti-cancer therapy. This allows your body time to remove and inactivate the chemotherapy. After a day of rest, you will be given your donor's cells.
Levetiracetam in Sodium Chloride Injection is for intravenous infusion only. It is available in the following concentrations: three single-dose 100 mL bags, each containing a different total dosage of levetiracetam (500 mg [5 mg/mL], 1,000 mg [10 mg/mL], or 1,500 mg [15 mg/mL]).

A single-dose bag should be administered intravenously over a 15-minute IV infusion period. 

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. 

Levetiracetam in Sodium Chloride Injection should not be further diluted prior to use. Any unused portion of the Levetiracetam in Sodium Chloride Injection contents should be discarded.
PURPOSE:To provide a hair cosmetic such as set lotion, hair spray, etc. containing a specific organic silicone resin and a volatile hydrocarbon oil, giving excellent gloss and smooth feeling to the hair, and having high set-keeping property. CONSTITUTION:The objective hair cosmetic contains (A) 0.1-50wt% organic silicone resin of formula (R is 1-6C hydrocarbon group or phenyl; n is 1.0-1.8) and (B) 0.1-99wt% volatile hydrocarbon oil having a boiling point of 60-260 deg.C. When the amount of the component B is high, the cosmetic has the form of a solution, and turns gradually to a solid state by increasing the amount of the component A. An emulsified composition can be produced by compounding the composition further with an aqueous component and a proper surfactant to an extent to keep the water-repellency. It may be compounded further with liquid paraffin, squalane, higher alcohol, medicinal drug component, perfumery, etc.